Scale-down of the inactivated polio vaccine production process

Biotechnology and Bioengineering

Volumn 110, Issue 5, 2013, Pages 1354-1365

  Thomassen, Yvonne E ^a   van 't Oever, Aart G ^a   Vinke, Marian ^a   Spiekstra, Arjen ^a   Wijffels, René H ^b   van der Pol, Leo A ^a   Bakker, Wilfried A M ^a  

^a Process Development   (Netherlands)

^b WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

Downscale; Downstream processing; IPV; Upstream processing; Vero cells

Indexed keywords

DOWNSCALE; DOWNSTREAM-PROCESSING; ION EXCHANGE CHROMATOGRAPHY; IPV; LARGE-SCALE MANUFACTURING; PRODUCTION CAPACITY; PRODUCTION PROCESS; VERO CELLS;

CHROMATOGRAPHIC ANALYSIS; CHROMATOGRAPHY; LABORATORIES; MANUFACTURE; OPTIMIZATION; VACCINES; VIRUSES;

PRODUCTION ENGINEERING;

INACTIVATED VACCINE; POLIOMYELITIS VACCINE;

ARTICLE; DRUG MANUFACTURE; GEL PERMEATION CHROMATOGRAPHY; ION EXCHANGE CHROMATOGRAPHY; LABORATORY; NONHUMAN; VERO CELL;

ANIMALS; BIOTECHNOLOGY; CELL CULTURE TECHNIQUES; CERCOPITHECUS AETHIOPS; CHROMATOGRAPHY, LIQUID; FORMALDEHYDE; POLIOVIRUS; POLIOVIRUS VACCINE, INACTIVATED; VERO CELLS; VIRUS INACTIVATION;

EID: 84875516309     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.24798     Document Type: Article

References (31)

1. Bakker WAM, Thomassen YE, van der Pol LA. 2010. Scale-down approach for animal-free polio vaccine production. In: Noll T, editor. Cells and culture; Proceedings of the 20th ESACT Meeting, Dresden, Germany, June 17-20, 2007: Springer Netherlands: 541-550.
2. Bakker WAM, Thomassen YE, van 't Oever AG, Westdijk J, van Oijen MGCT, Sundermann LC, van 't Veld P, Sleeman E, van Nimwegen FW, Hamidi A, Kersten GF, van den Heuvel N, Hendriks JT, van der Pol LA. 2011. Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV. Vaccine 29(41): 7188-7196.
3. Croughan MS, Hamel JF, Wang DI. 2006. Hydrodynamic effects on animal cells grown in microcarrier cultures, 1987. Biotechnol Bioeng 95(2): 295-305.
4. Food, and Drug Administration. 2001. Guidance for industry. Statistical approaches to establishing bioequivalence. Rockville, MD.
5. Godavarti R, Petrone J, Robinson J, Wright R, Kelly BD. 2005. Scale-down models for purification processes: Approaches and applications. In: Rathore AS, Sofer G, editors. Process validation in manufacturing of biopharmaceuticals: Guidelines, current practices, and industrial case studies. Boca Raton: CRC Press.
6. ICH Q10. 2008. Harmonized tripartite guideline on pharmaceutical quality system.
7. ICH Q8(R2). 2009. Harmonized tripartite guideline on pharmaceutical development.
8. ICH Q9. 2005. Harmonized tripartite guideline on quality risk management.
9. Koch F, Koch G. 1985. The molecular biology of poliovirus. Wien: Springer-Verlag.
10. Li F, Hashimura Y, Pendleton R, Harms J, Collins E, Lee B. 2006. A systematic approach for scale-down model development and characterization of commercial cell culture processes. Biotechnol Prog 22(3): 696-703.
11. Lycke E, Melen B, Wrange G. 1957. Studies of the inactivation of poliomyelitis virus by formaldehyde. Arch Gesamte Virusforsch 7(4): 378-383.
12. Montagnon BJ, Fanget B, Vincent-Falquet JC. 1984. Industrial-scale production of inactivated poliovirus vaccine prepared by culture of Vero cells on microcarrier. Rev Infect Dis 6(Suppl. 2): S341-S344.
13. Moreira JL, Cruz PE, Santana PC, Feliciano AS, Lehmann J, Carrondo MJT. 1995. Influence of power input and aeration method on mass transfer in a laboratory animal cell culture vessel. J Chem Technol Biotechnol 62(2): 118-131.
14. Nathanson N, Langmuir AD. 1963. The Cutter Incident. Poliomyelitis Following Formaldehyde Inactivated Poliovirus Vaccination in the United States during the Spring of 1955. II. Relationship of poliomyelitis to cutter vaccine. Am J Hyg 78: 29-60.
15. Nienow AW. 2006. Reactor engineering in large scale animal cell culture. Cytotechnology 50(1-3): 9-33.
16. Perry LA, Montgomery DC, Fowler JW. 2007. A partition experimental design for a sequential process with a large number of variables. Qual Reliab Eng Int 23(5): 555-564.
17. Pieracci J, Perry L, Conley L. 2010. Using partition designs to enhance purification process understanding. Biotechnol Bioeng 107(5): 814-824.
18. Rathore A, Krishnan R, Tozer S, Smiley D, Rausch S, Seely J. 2005a. Scaling down of biopharmaceutical unit operations-Part 2: Chromatography and filtration. BioPharm Int 18(4): 58-64.
19. Rathore A, Krishnan R, Tozer S, Smiley D, Rausch S, Seely J. 2005b. Scaling down of biopharmaceutical unit operations-Part I: Fermentation. BioPharm Int 18(3): 60-68.
20. Salk JE. 1953. Studies in human subjects on active immunization against poliomyelitis. I. A preliminary report of experiments in progress. J Am Med Assoc 151(13): 1081-1098.
21. Schuirmann DJ. 1987. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 15(6): 657-680.
22. ten Have R, Thomassen YE, Hamzink MRJ, Bakker WAM, Nijst OEM, Kersten G, Zomer G. 2012. Development of a fast ELISA for quantifying polio D-antigen in in-process samples. Biologicals 40(1): 84-87.
23. Thomassen YE, van Sprang ENM, van der Pol LA, Bakker WAM. 2010. Multivariate data analysis on historical IPV production data for better process understanding and future improvements. Biotechnol Bioeng 107(1): 96-104.
24. Thomassen YE, van der Welle JE, van Eikenhorst G, van der Pol LA, Bakker WAM. 2012. Transfer of an adherent Vero cell culture method between two different rocking motion type bioreactors with respect to cell growth and metabolic rates. Process Biochem 47(2): 288-296.
25. van der Velden-de Groot CAM. 1995. Microcarrier technology, present status and perspective. Cytotechnology 18(1-2): 51-56.
26. van Steenis G, van Wezel AL, Sekhuis VM. 1981. Potency testing of killed polio vaccine in rats. Dev Biol Stand 47: 119-128.
27. van 't Riet K, Tramper J. 1991. Basic bioreactor design. New York: Marcel Dekker, Inc.
28. van Wezel AL. 1967. Growth of cell-strains and primary cells on micro-carriers in homogeneous culture. Nature 216(5110): 64-65.
29. van Wezel AL. 1985. Monolayer growth systems: Homogeneous unit processes. In: Spier RE, Griffith JB, editors. Animal cell biotechnology. London: Academic Press. p 265-282.
30. van Wezel AL, van SG, van der MP, Osterhaus AD. 1984. Inactivated poliovirus vaccine: Current production methods and new developments. Rev Infect Dis 6: (Suppl. 2): S335-S340.
31. Zwietering TN. 1958. Suspending of solid particles in liquid by agitators. Chem Eng Sci 8(3-4): 244-253.